Disintegrin and metalloproteinase domain-containing protein 12 (ADAM12) (ADAM12)

Disintegrin and metalloproteinase domain-containing protein 12 (ADAM12) is a multidomain enzyme belonging to the ADAM family, characterized by its roles in cell-surface proteolysis and cell-matrix interactions [UniProt: O43184]. It exists in two main isoforms: a transmembrane form (ADAM12-L) and a secreted form (ADAM12-S), both of which are involved in the shedding of various cell surface molecules, including growth factors like HB-EGF and insulin-like growth factor-binding proteins [PubMed: 22461458]. ADAM12 is typically expressed at low levels in normal adult tissues but is significantly upregulated in various pathological conditions, particularly in aggressive cancers and fibrotic diseases [PubMed: 25650134]. In oncology, high expression of ADAM12 is associated with epithelial-mesenchymal transition (EMT), tumor progression, and poor clinical outcomes, making it a valuable prognostic biomarker and a potential therapeutic target [NCBI Gene: 8038]. Therapeutic strategies focusing on ADAM12 mRNA, such as antisense oligonucleotides and siRNA, aim to reduce its expression to inhibit tumor growth and metastasis. While specific small-molecule inhibitors have faced challenges regarding selectivity, targeting the mRNA provides a more specific approach to modulating ADAM12 activity in disease states.

Other names

Meltrin-alphaMCMPMLTNADAM metallopeptidase domain 12

mRNA degradation via antisense or RNA interference mechanisms; inhibition of proteolytic shedding of growth factors.